Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
3.8
Journals
Viruses
Special Issues
Novel Strategies to Identify and Eliminate Latent HIV Cells
share announcement

Novel Strategies to Identify and Eliminate Latent HIV Cells

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2700

Special Issue Editor

Dr. Francesco Andrea Procopio

E-Mail
Guest Editor
CHUV, Divison of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland
Interests: HIV; HIV reservoir; quantification of HIV DNA and RNA; single cells analysis; HIV reactivation; HIV cure; HIV vaccines

Special Issue Information

Dear Colleagues,

Due to the availability of antiretroviral therapy (ART), HIV-1 infection has transitioned into a chronic condition. ART effectively suppresses plasma viral loads to undetectable levels, thereby preventing the progression to AIDS. However, the virus remains latent and persists in the body, posing a significant challenge to achieving a cure. If ART is discontinued, the virus rebounds, necessitating lifelong medication for those affected.

Cutting-edge technologies have dramatically enhanced our understanding of HIV-1 infection at the single-cell level (for example, HIVseq, FINDseq, viral ASAPseq), facilitating remarkable progress in the field.

Despite numerous setbacks in the quest for a cure, novel therapeutic approaches have already reached the clinical trial stage, and new strategies are continually being proposed and implemented (for example CRISPR, targeted lipid nanoparticles, broadly neutralizing antibodies, AZD5582, trimeric Env, TLR7 agonist, anti-HIV CAR-T and/or a combination of them).

The objective of this Special Issue of Viruses is to examine and discuss recent advancements in the analysis of HIV-1 viral infection at the single-cell level, as well as the latest ongoing efforts in developing new cure strategies. 

Dr. Francesco Andrea Procopio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV
  • HIV-1 infection
  • antiretroviral therapy (ART)

  • HIV single cell analysis

  • HIV reservoir
  • HIV cure

 

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 5726 KiB  
Article
Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors
by Hasset Tibebe, Dacia Marquez, Aidan McGraw, Sophia Gagliardi, Cailyn Sullivan, Grace Hillmer, Kedhar Narayan, Coco Izumi, Adleigh Keating and Taisuke Izumi
Viruses 2025, 17(3), 400; https://doi.org/10.3390/v17030400 - 12 Mar 2025
Viewed by 2010
Abstract
The “Kick and Kill” strategy, which aims to reactivate latent HIV reservoirs and facilitate the clearance of reactivated HIV-infected cells, has yet to achieve a functional cure due to the limited efficacy of current latency reversal agents. This study evaluates the combination efficacy [...] Read more.
The “Kick and Kill” strategy, which aims to reactivate latent HIV reservoirs and facilitate the clearance of reactivated HIV-infected cells, has yet to achieve a functional cure due to the limited efficacy of current latency reversal agents. This study evaluates the combination efficacy of histone deacetylase (HDAC) inhibitor with poly(ADP-ribose) polymerase (PARP) inhibitor in latency reversal and immune-mediated clearance. Latently infected J-Lat cells and dual-fluorescent HIV-infected primary CD4 T cells were treated with the HDAC inhibitor (vorinostat) and one of four PARP inhibitors (olaparib, rucaparib, niraparib, or talazoparib). PARP inhibitors, when administered alone, showed no latency reversal activity. However, when combined with vorinostat, their efficacy increased threefold compared to vorinostat alone. This effect was mediated by the inhibition of tankyrase, a PARP superfamily member, which modulates the Hippo signaling pathway. In HIVGR670-infected primary cells, the combination reduced the reservoir size by 67%. In addition, talazoparib alone significantly reduced actively infected cells by 50%. Talazoparib-treated peripheral blood mononuclear cells co-cultured with K562 cells demonstrated enhanced NK-cell-mediated cytotoxicity, with a 10% reduction in K562 cell viability. These findings demonstrate that combining HDAC and PARP inhibitors augments latency reversal and reservoir reduction. With both the HDAC inhibitors and PARP inhibitors used in this study approved by the FDA for cancer treatment, this combination therapy holds strong potential for rapid clinical integration, contingent upon the confirmation of efficacy and safety in ongoing in vivo studies. Full article
(This article belongs to the Special Issue Novel Strategies to Identify and Eliminate Latent HIV Cells)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop